JP2024513003A - Csf1rアンタゴニストに対する耐性を付与するための哺乳動物細胞の遺伝子改変 - Google Patents

Csf1rアンタゴニストに対する耐性を付与するための哺乳動物細胞の遺伝子改変 Download PDF

Info

Publication number
JP2024513003A
JP2024513003A JP2023559849A JP2023559849A JP2024513003A JP 2024513003 A JP2024513003 A JP 2024513003A JP 2023559849 A JP2023559849 A JP 2023559849A JP 2023559849 A JP2023559849 A JP 2023559849A JP 2024513003 A JP2024513003 A JP 2024513003A
Authority
JP
Japan
Prior art keywords
csf1r
cell
modified
cells
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023559849A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513003A5 (cg-RX-API-DMAC7.html
Inventor
ダフチャン、ハイク
ハッセルマン、ジョナサン
- ジョーンズ、マシュー ブラートン
チャダレビアン、ジャン、ポール
スピテール、ロバート
ガンジー、スニール
イングランド、ホイットニー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of JP2024513003A publication Critical patent/JP2024513003A/ja
Publication of JP2024513003A5 publication Critical patent/JP2024513003A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
JP2023559849A 2021-04-01 2022-04-01 Csf1rアンタゴニストに対する耐性を付与するための哺乳動物細胞の遺伝子改変 Pending JP2024513003A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163169578P 2021-04-01 2021-04-01
US63/169,578 2021-04-01
US202163236951P 2021-08-25 2021-08-25
US63/236,951 2021-08-25
PCT/US2022/023139 WO2022212897A1 (en) 2021-04-01 2022-04-01 Genetic modification of mammalian cells to confer resistance to csf1r antagonists

Publications (2)

Publication Number Publication Date
JP2024513003A true JP2024513003A (ja) 2024-03-21
JP2024513003A5 JP2024513003A5 (cg-RX-API-DMAC7.html) 2025-04-03

Family

ID=83456857

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023559849A Pending JP2024513003A (ja) 2021-04-01 2022-04-01 Csf1rアンタゴニストに対する耐性を付与するための哺乳動物細胞の遺伝子改変

Country Status (8)

Country Link
US (3) US20230248775A1 (cg-RX-API-DMAC7.html)
EP (1) EP4314003A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024513003A (cg-RX-API-DMAC7.html)
AU (1) AU2022252407A1 (cg-RX-API-DMAC7.html)
CA (1) CA3215311A1 (cg-RX-API-DMAC7.html)
DE (4) DE202022003132U1 (cg-RX-API-DMAC7.html)
GB (1) GB2612467B (cg-RX-API-DMAC7.html)
WO (1) WO2022212897A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12612599B2 (en) 2018-09-10 2026-04-28 Savanna Biotherapeutics, Inc. Compositions and methods for microglia replacement therapy
DE202022003132U1 (de) * 2021-04-01 2025-02-17 The Regents Of The University Of California Genetische Modifikation von Säugerzellen zur Verleihung von Resistenz gegen CSF1R-Antagonisten

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040161821A1 (en) * 2002-11-26 2004-08-19 Cold Spring Harbor Laboratory DEP-1 receptor protein tyrosine phosphatase interacting proteins and related methods

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9044503B2 (en) 2004-08-27 2015-06-02 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
WO2006069203A2 (en) 2004-12-22 2006-06-29 California Institute Of Technology Methods for proteomic profiling using non-natural amino acids
WO2009089635A1 (en) 2008-01-16 2009-07-23 Neurodyn, Inc. Treating neurodegenerative diseases with progranulin (pgrn)
KR20100054711A (ko) 2008-11-14 2010-05-25 메디포스트(주) 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
EP2424976B1 (en) 2009-04-28 2013-07-31 Life & Brain GmbH Method for obtaining human microglial precursor cells from pluripotent stem cells
US8765117B2 (en) 2009-06-10 2014-07-01 The General Hospital Corporation Generation of vascularized human heart tissue and uses thereof
CA2818253A1 (en) 2010-11-16 2012-05-24 Denis G. Kay Method for increasing neprilysin expression and activity
CA2831609C (en) 2011-03-30 2019-06-11 Cellular Dynamics International, Inc. Priming of pluripotent stem cells for neural differentiation
EP3092305B1 (en) 2014-01-09 2023-08-02 Kyushu University, National University Corporation Method of producing microglial cells
US10081792B2 (en) 2014-12-31 2018-09-25 Wisconsin Alumni Research Foundation Derivation of human microglia from pluripotent stem cells
CA2972598C (en) 2014-12-31 2024-03-12 Wisconsin Alumni Research Foundation Human pluripotent stem cell-based models for predictive developmental neural toxicity
JP6774952B2 (ja) 2015-01-16 2020-10-28 エージェンシー フォー サイエンス, テクノロジー アンド リサーチ 多能性幹細胞のマクロファージへの分化
US10626372B1 (en) 2015-01-26 2020-04-21 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
WO2016210313A1 (en) 2015-06-24 2016-12-29 Whitehead Institute For Biomedical Research Culture medium for generating microglia from pluripotent stem cells and related methods
CA3016575A1 (en) 2016-03-03 2017-09-08 New York Stem Cell Foundation, Inc. Microglia derived from pluripotent stem cells and methods of making and using the same
WO2017223199A1 (en) 2016-06-22 2017-12-28 Xcell Biosciences, Inc. Methods for increasing cell culture transfection efficiency and cellular reprogramming
CN109963940A (zh) 2016-09-02 2019-07-02 宝生物工程株式会社 从多能干细胞获得小胶质细胞的方法
CA3038690A1 (en) 2016-10-05 2018-04-12 FUJIFILM Cellular Dynamics, Inc. Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
CN110621774A (zh) 2016-10-14 2019-12-27 儿童医疗中心有限公司 用于治疗中枢神经系统疾病和病症的组合物和方法
WO2018160496A1 (en) 2017-02-28 2018-09-07 The Regents Of The University Of California Differentiation and use of human microglia-like cells from pluripotent stem cells and hematopoietic progenitors
WO2019118951A2 (en) 2017-12-15 2019-06-20 Duke University Compositions and methods of enhancing the homing and/or engraftment of hematopoietic cells in the central nervous system
US12171764B2 (en) * 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
WO2020033791A1 (en) * 2018-08-09 2020-02-13 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
US12612599B2 (en) * 2018-09-10 2026-04-28 Savanna Biotherapeutics, Inc. Compositions and methods for microglia replacement therapy
CN113166219A (zh) 2018-09-28 2021-07-23 纪念斯隆-凯特琳癌症中心 干细胞衍生的人小神经胶质细胞、制备方法及使用方法
US12419915B2 (en) 2019-03-13 2025-09-23 The Broad Institute, Inc. Microglial progenitors for regeneration of functional microglia in the central nervous system and therapeutics uses thereof
WO2020232512A1 (en) 2019-05-22 2020-11-26 The Council Of The Queensland Institute Of Medical Research Microglial cells and methods of use thereof
WO2020252477A1 (en) 2019-06-14 2020-12-17 FUJIFILM Cellular Dynamics, Inc. Methods for the production of multiple lineages from induced pluripotent stem cells using charged surfaces
EP4010361A4 (en) 2019-08-06 2023-08-09 Children's Medical Center Corporation METHODS AND COMPOSITIONS FOR RESTORING MICROGLIA
TWI799733B (zh) 2019-08-26 2023-04-21 臺北榮民總醫院 一種從體細胞製備誘導性多能幹細胞之方法
WO2021221879A1 (en) 2020-05-01 2021-11-04 Albert Einstein College Of Medicine Compositions and methods for using transplanted microglia as a vehicle for widespread delivery of cells and other biologic agents to the brain
US20240117431A1 (en) 2020-06-02 2024-04-11 The Regents Of The University Of California Stem-cell based biomarker discovery
GB202011871D0 (en) 2020-07-30 2020-09-16 Cambridge Entpr Ltd Composition and method
EP4204544A4 (en) 2020-08-25 2024-10-30 University Health Network COMPOSITIONS AND METHODS FOR GENERATING HUMAN YOLK SAC-TYPE HEMATOPOIETIC CELLS
DE202022003132U1 (de) 2021-04-01 2025-02-17 The Regents Of The University Of California Genetische Modifikation von Säugerzellen zur Verleihung von Resistenz gegen CSF1R-Antagonisten

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040161821A1 (en) * 2002-11-26 2004-08-19 Cold Spring Harbor Laboratory DEP-1 receptor protein tyrosine phosphatase interacting proteins and related methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COMPUT BIOL CHEM., vol. 80, JPN6026004493, pages 374 - 383, ISSN: 0005789294 *
PLOS ONE, vol. 11(7):e0160165, JPN6026004490, 2016, ISSN: 0005789292 *
SCI REP., vol. 22:3:3013, JPN6026004492, 2013, ISSN: 0005789293 *

Also Published As

Publication number Publication date
US20250002920A1 (en) 2025-01-02
GB2612467A (en) 2023-05-03
EP4314003A1 (en) 2024-02-07
AU2022252407A1 (en) 2023-10-12
DE202022003066U1 (de) 2024-09-19
EP4314003A4 (en) 2025-03-12
DE202022002866U1 (de) 2024-03-20
US20230203500A1 (en) 2023-06-29
DE112022000079T5 (de) 2023-06-15
DE202022003132U1 (de) 2025-02-17
AU2022252407A9 (en) 2023-10-26
WO2022212897A1 (en) 2022-10-06
GB202219686D0 (en) 2023-02-08
US20230248775A1 (en) 2023-08-10
GB2612467B (en) 2025-11-19
CA3215311A1 (en) 2022-10-06
US12421517B2 (en) 2025-09-23

Similar Documents

Publication Publication Date Title
Krämer et al. Bruton tyrosine kinase inhibitors for multiple sclerosis
JP2022046822A (ja) 中枢神経系の疾患および障害を処置するための組成物および方法
Chun et al. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya)
US20250002920A1 (en) Genetic modification of mammalian cells to confer resistance to csf1r antagonists
US20080269123A1 (en) Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
Shin et al. Combined effects of hematopoietic progenitor cell mobilization from bone marrow by granulocyte colony stimulating factor and AMD3100 and chemotaxis into the brain using stromal cell‐derived factor‐1α in an Alzheimer's disease mouse model
JP2021535152A (ja) 神経変性障害を処置するためのripキナーゼの阻害法
Li et al. Lipocalin-2-Mediated Insufficient Oligodendrocyte Progenitor Cell Remyelination for White Matter Injury After Subarachnoid Hemorrhage via SCL22A17 Receptor/Early Growth Response Protein 1 Signaling: Q. Li et al.: LCN2-mediated White Matter Injury after SAH
US20190216891A1 (en) Method for modulating myelination
JP2017506259A (ja) 幹細胞を枯渇させるためのカゼインキナーゼi阻害剤の使用
CN113194956A (zh) 用于癌症治疗的cxcr7抑制剂
JP6429191B2 (ja) アポトーシスシグナル伝達抵抗性細胞を選択する装置および方法ならびにその使用
KR20250020536A (ko) 타우 단백질 집적 억제용 조성물 및 집적억제 방법
CN112584845A (zh) 用于调节髓过氧化物酶(mpo)表达的方法和组合物
CN117580871A (zh) 哺乳动物细胞的基因修饰赋予对csf1r拮抗剂的抗性
WO2019146805A1 (ja) 前頭側頭葉変性症治療剤、前頭側頭葉変性症治療剤のスクリーニング方法、及び前頭側頭葉変性症の治療方法
CN114617969B (zh) 乐伐替尼和Aurora-A激酶抑制剂在制备抑制癌症的药物中的应用
WO2021188349A2 (en) Methods of treating mitochondrial disorders
TWI598101B (zh) 用於心臟再生的治療性基因混合製劑
Han Repopulation of a microglia-depleted central nervous system: molecular characterization during homeostasis and disease
Yu Optimizing the Therapeutic Index for Medulloblastoma by Targeting Apoptosis
Zhu Deciphering and fine-tuning of myeloid cells in CNS demyelinating conditions
Thompson Therapeutic Targeting of Glial Cells in Central Nervous System Inflammatory Demyelinating Disease
Wheeler Autotaxin in Central Nervous System Development and Disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260803